Salidroside alleviates cigarette smoke-induced COPD in mice

详细信息    查看全文

• 作者：Fen Luo ; Jingyan Liu ; Tianhua Yan ; ^{yantianhuabest@126.com} ; Mingxing Miao ; ^{miaomingxingcpu@126.com}
• 关键词：Salidroside ; COPD ; Inflammation
• 刊名：Biomedicine & Pharmacotherapy
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：86
• 期：Complete
• 页码：155-161
• 全文大小：1796 K
• 卷排序：86

文摘

The present study was to evaluate the effects of salidroside (Sal) on CS (cigarette smoke)-induced COPD in mice and explore its underlying mechanisms. 50 male ICR mice were randomly assigned to five groups: control group, CS group, CS + dexamethasone (2 mg/kg) group, CS + salidroside (20 mg/kg) group and CS + salidroside (40 mg/kg) group. The COPD mice were induced by CS exposure for 8 weeks. The results of H&E staining demonstrated that Sal alleviated CS-induced pathological injury in lungs. Besides, Sal increased the activities of superoxide dismutase (SOD), reduced the content of malondialdehyde (MDA) in serum. Sal also inhibited the generations of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) in serum and lungs. Furthermore, the administration of Sal significantly inhibited the protein levels of MAPK/NF-κB pathway in CS-induced mice. Our findings showed that Sal might effectively ameliorate the progression of COPD via MAPK/NF-κB pathway.